ProMetic Life Sciences Inc.: Official Signing Ceremony for WIBP
Strategic Alliance
MONTREAL, QUEBEC -- (MARKET WIRE) -- 06/05/08 -- ProMetic Life
Sciences Inc. (TSX: PLI) ("ProMetic") announced today that the
official signing ceremony for the strategic alliance concluded
earlier this year with the Wuhan Institute of Biological Products
("WIBP") a subsidiary of China National Biotec Group ("CNBG") was
held on Wednesday, June 4, 2008 at CNBG's Beijing location.
Present at the signing were CNBG's President and Chief Executive
Officer Ms. Lifeng Wang, WIBP's Director Dr. Xiaoming Yang,
ProMetic's President and Chief Executive Officer Mr. Pierre Laurin as
well as several officials from the CNBG and WIBP organizations.
Additional information is available on CNBG's web site at
www.cnbgint.com and on WIBP's web site at www.wibp.com.cn/en.
More about Wuhan Institute of Biological Products
WIBP (www.wibp.com.cn or www.wibp.com.cn), located in Wuhan, China.
is one of the subsidiaries of CNBG, has over 50 years experience in
the fields of biomedical research and product development;
historically strong in R&D, WIBP is the only institute certified by
state to offer doctoral program among six Institute of Biological
Products in CNBG. Today, WIBP has more than 1,000 employees, and
major products include two dozen vaccines and plasma derivatives
currently marketed throughout the China.
More about China National Biotec Group
CNBG (www.cnbgint.com or www.cnbg.com.cn), headquartered in Beijing,
China, is a state-owned enterprise and the largest biotech company in
China dedicated to discover, develop, manufacture and market a broad
range of human health products, including vaccines, blood
derivatives, biopharmaceuticals, diagnostic reagents and others. With
more than 9,000 employees and revenues of 421 million USD in 2006,
CNBG is the largest producer of vaccines and blood derivatives in
China, enjoying more than 80% and 30% market share respectively. The
company consists of 6 Institute of Biological Products and an
international trading company.
About ProMetic Life Sciences Inc.
ProMetic (www.prometic.com) is a biopharmaceutical company
specialized in the research, development, manufacture and marketing
of a variety of commercial applications derived from its proprietary
Mimetic Ligand(TM) technology. This technology is used in large-scale
purification of biologics and the elimination of pathogens. ProMetic
is also active in therapeutic drug development with the mission to
bring to market effective, innovative, lower cost, less toxic
products for the treatment of hematology and cancer. Its drug
discovery platform is focused on replacing complex, expensive
proteins with synthetic "drug-like" protein mimetics. Headquartered
in Montreal (Canada), ProMetic has R&D facilities in the U.K., the
U.S. and Canada, manufacturing facilities in the U.K. and business
development activities in the U.S., Europe, Asia and in the
Middle-East.
Contacts:
Company Inquiries:
ProMetic Life Sciences Inc.
Pierre Laurin
President and CEO
1-514-341-2115
p.laurin@prometic.com
ProMetic Life Sciences Inc.
Anne Leduc
Manager, Investor Relations & Communications
1-514-341-2115
a.leduc@prometic.com
Echoes Financial Network Inc.
Dominic Sicotte
1-514-842-9551
dsicotte@echoesfinancial.com
Investor Relations:
Lippert / Heilshorn & Associates
Bruce Voss
1-310-691-7100
BVoss@lhai.com
Lippert / Heilshorn & Associates
Kim Golodetz
1-212-838-3777
KGolodetz@lhai.com
Media Relations:
Lippert / Heilshorn & Associates
Jules Abraham
1-212-838-3777
JAbraham@lhai.com
